SCHEMBL22493310

SCHEMBL22493310

COc1cc(N2CCN(C(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 20/20 0.83
INSR P06213 16/20 0.83
IGF1R P08069 16/20 0.83
AURKA O14965 2/20 0.76
ROS1 P08922 2/20 0.76
EML4 Q9HC35 2/20 0.76
EGFR P00533 2/20 0.75
CHEK1 O14757 1/20 0.73
NUAK1 O60285 1/20 0.73
JAK2 O60674 1/20 0.73
STK10 O94804 1/20 0.73
PRKD3 O94806 1/20 0.73
SLC34A2 O95436 1/20 0.73
CHEK2 O96017 1/20 0.73
ABL1 P00519 1/20 0.73
CD74 P04233 1/20 0.73
ERBB2 P04626 1/20 0.73
LCK P06239 1/20 0.73
FYN P06241 1/20 0.73
FES P07332 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11916461 0.93 INSR (0.85) ALKINSRIGF1RAURKAROS1
SCHEMBL11916443 0.91 ALK (1.00) ALKINSRIGF1RAURKAROS1
SCHEMBL11916595 0.90 ALK (0.86) ALKINSRIGF1RAURKAROS1
SCHEMBL22793620 0.90 ALK (0.82) ALKINSRIGF1RAURKAROS1
SCHEMBL28680439 0.89 ALK (0.84) ALKINSRIGF1RAURKAROS1
SCHEMBL11916493 0.89 ALK (0.84) ALKINSRIGF1RAURKAROS1
SCHEMBL11916495 0.89 ALK (0.83) ALKINSRIGF1RAURKAROS1
SCHEMBL11916582 0.89 ALK (0.91) ALKINSRIGF1RAURKAROS1
SCHEMBL24818137 0.89 ALK (0.83) ALKINSRIGF1RAURKAROS1
SCHEMBL21135587 0.89 ALK (0.86) ALKINSRIGF1RAURKAROS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771709-B2 ALK protein degradation agent and anti-tumor application thereof SHANGHAITECH UNIVERSITY (CN) 2023-10-03 US disclosed
US-11771709-B2 ALK protein degradation agent and anti-tumor application thereof SHANGHAITECH UNIVERSITY (CN) 2023-10-03 US disclosed
US-20200306273-A1 ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF SHANGHAITECH UNIVERSITY (CN) 2020-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200306273-A1 ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF ADRM1, VHL, MDM2 ALK 5/4885INSR 1929/4885IGF1R 306/4885
US-11771709-B2 ALK protein degradation agent and anti-tumor application thereof ADRM1, VHL, MDM2 ALK 5/4885INSR 1929/4885IGF1R 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.